Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non - Nucleoside Polymerase and Protease Inhibitors
نویسندگان
چکیده
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam, Ying Ou, 4 Karl Frank, Thierry Lave, and Patrick Smith 5 Affiliations: 1 Hoffmann-La Roche Inc., Nutley, NJ ; 2 Current affiliation Theravance, 6 South San Francisco, CA; 3 Work done while at Roche Palo Alto, Palo 7 Alto, CA; 4 Hoffmann-La Roche, Basel, Switzerland. 8 9 Corresponding Author: 10 Micaela Reddy 11 Hoffmann-La Roche Inc. 12 340 Kingsland St. 13 Nutley, NJ 07110-1199 14 Phone: 973-235-7529 15 Fax: 973-235-4710 16 E-mail: [email protected] 17
منابع مشابه
Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.
This analysis was conducted to determine whether the hepatitis C virus (HCV) viral kinetics (VK) model can predict viral load (VL) decreases for nonnucleoside polymerase inhibitors (NNPolIs) and protease inhibitors (PIs) after 3-day monotherapy studies of patients infected with genotype 1 chronic HCV. This analysis includes data for 8 NNPolIs and 14 PIs, including VL decreases from 3-day monoth...
متن کاملDevelopment of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors.
There is a need for models useful for predicting the efficacy of agents developed for treating human immunodeficiency virus (HIV) based on information obtained during the drug development process. A pharmacodynamic model that superimposes the pharmacokinetics of anti-HIV nucleoside reverse transcription (RT) and protease inhibitors over a previously published predator-prey model of HIV and CD4 ...
متن کاملThe hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
Specific inhibitors of hepatitis C virus (HCV) replication that target the NS3/4A protease (e.g., VX-950) or the NS5B polymerase (e.g., R1479/R1626, PSI-6130/R7128, NM107/NM283, and HCV-796) have advanced into clinical development. Treatment of patients with VX-950 or HCV-796 rapidly selected for drug-resistant variants after a 14-day monotherapy treatment period. However, no viral resistance w...
متن کاملThe Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed toward specific proteins involved in hepatitis C replication with NS3/NS4A protease inhibitors fu...
متن کاملExistence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
OBJECTIVES To characterize the effect of hepatitis C virus (HCV) polymerase intrinsic genetic heterogeneity on the inhibitory activity of nucleoside and non-nucleoside HCV polymerase inhibitors. METHODS The sensitivity of genotype (GT) 1 HCV NS5B clinical isolates from treatment-naive patients to nucleoside and non-nucleoside polymerase inhibitors was assessed. The genetic diversity at the po...
متن کامل